Trial to Investigate the Efficacy and the Safety of Thrice-Daily NN2000-Mix70 (NovoRapid 70 Mix) Compared to Twice-Daily NN-X14Mix30 (NovoRapid 30 Mix) in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2017
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 20 May 2009 Actual number of patients (289) and actual end date (1 Jun 2007) added as reported by ClinicalTrials.gov.
- 05 Sep 2007 Status changed from in progress to completed.